After several years of volatility and unfavorable market dynamics, the initial public offering (IPO) market for medical technology companies is beginning to reopen meaningfully. Following the most recent IPO boom in 2020 and 2021, higher interest rates and inflation brought new IPO issuances to a near standstill from 2022 to 2024. During that period, many medtech companies postponed plans to go public, creating a significant backlog of IPO deals.
LINKS
Read “From Innovation to IPO: A Strategic Checklist for Medtech Companies,” co-authored by David J. Dykeman and Michael Minahan, and published by Medical Product Outsourcing.